Holstein-Friesian RBC as human blood substitute.
10.7534/j.issn.1009-2137.2014.04.040
- Author:
Li-Ping CHEN
1
;
Su-Bo LI
2
;
Xue ZHANG
2
;
Feng GONG
2
;
Hong-Wei GAO
3
;
Hua XU
4
Author Information
1. Shaanxi Blood Center, Xi'an 710061,Shaanxi Province, China.
2. Department of Blood Molecular Biology, Beijing Institute of Transfusion Medicine, Beijing 100850, China.
3. Department of Blood Molecular Biology, Beijing Institute of Transfusion Medicine, Beijing 100850, China. E-mail: gaohongwei1976@126.com.
4. Shaanxi Blood Center, Xi'an 710061,Shaanxi Province, China. E-mail: drxuhua@163.com.com.
- Publication Type:Journal Article
- MeSH:
Animals;
Blood Substitutes;
Cattle;
Erythrocytes;
immunology;
Female;
Humans;
Transplantation, Heterologous
- From:
Journal of Experimental Hematology
2014;22(4):1099-1102
- CountryChina
- Language:Chinese
-
Abstract:
α-Gal, the main xenotransplantation antigen, can lead to hyperacute rejection (HAR) in xenotransplantation. This study was purposed to investigate the effect of recombinant α-galactosidase (α-Gal antigen) on the Holstein-Friesian(H-F) red blood cells (RBC). The enzymelysis method was used to digest the α-Gal antigen on H-F RBC; the saline and anti-human globulin methods were used to perform the agglutination test of H-F RBC and human plasma; the flow cytometry was used to detect the α-Gal antigen on surface of H-F RBC, fluorescence intensity of FITC-IB4 and FITC-IgG labeled RBC. The results indicated that the saline and anti-human globulin method showed α-galactosidase-treated H-F RBC fail to agglutinate with human pooled plasma; the flow cytometry showed the fluorescence intensity of FITC-IB4 and FITC-IgG labeled RBC decrease 99.0% and 87.8%, respectively. It is concluded that the novel α-galactosidase can be used to cleared the α-Gal antigen on the surface of H-F RBC and α-galactosidase-treated H-F RBC may be considered as human blood substitute.
